OneMedNet Accelerates AI Drug Development with Rapid Data Delivery Deal
Event summary
- OneMedNet's iRWD platform enabled cohort feasibility within minutes, data validation within a week, and contract signing within three weeks for an AI-driven drug development company.
- The deal involves delivering de-identified, full-fidelity clinical Real-World Data (RWD) to support AI model development and validation.
- OneMedNet's network exceeds 90 million patient journeys, 270 million studies, and 2,300 healthcare partner sites.
- The platform spans Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records.
The big picture
OneMedNet's deal highlights the growing reliance on high-fidelity, direct-from-source real-world data for AI-driven drug development. The platform's ability to rapidly deliver validated data positions it as critical infrastructure in the healthcare and life sciences ecosystem. The agreement underscores the strategic shift towards leveraging private clinical data to accelerate AI model development and validation, reflecting broader industry trends towards data-driven innovation in drug discovery.
What we're watching
- Data Quality
- How OneMedNet's direct-from-source data quality will impact AI model accuracy and regulatory approvals.
- Market Demand
- Whether the surge in demand for private healthcare clinical data can be sustained.
- Execution Pace
- The pace at which OneMedNet can scale its network and maintain rapid feasibility-to-delivery timelines.
Related topics